Previous 10 | Next 10 |
home / stock / rvmd / rvmd articles
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing n...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded down 0.19% to 33,06...
Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction. L...
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Here are some big stocks recording losses in toda...
U.S. stocks traded lower this morning, with the Dow Jones index falling over 100 points on Monday. Following the market opening Monday, The Dow tra...
REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing t...
U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Monday. Here are some stocks recording big gains in today’s ses...
Revolution Medicines Inc (NASDAQ: RVMD) released preliminary data for RMC-6236, its RASMULTI(ON) Inhibitor, and RMC-6291, its RASG12C(ON) Inhi...
Clinical dose escalation data for RMC-6236, a RASMULTI(ON) Inhibitor, show oral bioavailability, well-tolerated safety profile and preliminary e...
News, Short Squeeze, Breakout and More Instantly...
Revolution Medicines Inc. Company Name:
RVMD Stock Symbol:
NASDAQ Market:
Revolution Medicines Inc. Website:
2024-07-24 09:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-14 06:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) Re...